Hyphens Pharma International

What Hyphens Pharma International does

Hyphens Pharma International Limited is a Singapore-based pharmaceutical and consumer healthcare group, founded in 1998 and listed on the Singapore Exchange (SGX). The company develops, manufactures, and commercializes proprietary pharmaceutical products and health supplements, with its flagship asset being Cerapro® MED Skin Barrier Cream — a patented pH-lowering formulation approved as a Class I medical device under the European Medical Device Regulation (EU MDR) with CE marking, indicated for the treatment of atopic dermatitis.

The company operates a dual-channel commercial model: it distributes its own portfolio in Singapore and Southeast Asia through its sales-led infrastructure, and it out-licenses proprietary products to established regional partners for international commercialization in exchange for upfront fees, product supply revenues, and ongoing sales-based royalties. Its most consequential licensing arrangement is with Louis Widmer SA, a Swiss cosmetics and pharmaceuticals company founded in 1960, which was granted exclusive licensing, supply, and commercialization rights to Cerapro® MED across six European countries — Switzerland, Liechtenstein, Austria, Belgium, Luxembourg, and the Netherlands — with the European launch targeted for 2026. Under this agreement, Louis Widmer will promote Cerapro® MED to dermatologists and paediatricians and position it as the flagship product of its Remederm line.

Hyphens Pharma is led by founder Lim See Wah, who serves as Chairman, Managing Director, and CEO, and operates with a headcount of 101–250 employees. Revenue (scaled appropriately from reported figures) sits in the low-to-mid eight-figure USD range, with a product portfolio anchored by patented dermatology assets and an asset-light expansion model that leverages licensee distribution networks to access regulated markets without bearing full local commercialization costs. The company has been cited externally as an example of an SGX-listed firm that has translated strategic clarity and transparent governance into stronger market valuations.

Name

Hyphens Pharma International

Legal name

Hyphens Pharma International Limited

Website

https://hyphensgroup.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

101–250 employees

Short description

Hyphens Pharma International is a Singapore-based, SGX-listed pharmaceutical and consumer healthcare group that develops proprietary dermatology products — notably the CE-marked Cerapro® MED skin barrier cream — and commercializes them in Southeast Asia directly while out-licensing them to regional partners such as Louis Widmer SA for European expansion.

Ownership category

akta.pro rank

Product category

Dermatology Pharmaceuticals and Medical Devices

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391)

SIC

Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industries

Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Sensitive Skin & Barrier Repair (CRABAAAG), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

• Pharmaceutical products
• Medical device dermatology
• Skin barrier treatment
• Consumer healthcare products
• Pharmaceutical licensing

Headquarters

HQ city

Hougang

HQ country

Singapore

HQ region

Asia

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Licensing and Royalties: Hyphens Pharma receives upfront payments and ongoing royalties on sales for its licensed products. The company out-licenses proprietary pharmaceutical products to regional partners for commercialization in exchange for licensing fees and sales-based royalties.
2. Product Supply: Under licensing agreements, Hyphens Pharma supplies Cerapro® MED products to its licensing partners such as Louis Widmer SA, generating revenue through product supply alongside licensing fees.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Core offering

Hyphens Pharma International is a Singapore-based pharmaceutical and consumer healthcare group that develops, manufactures, and commercializes proprietary pharmaceutical products and health supplements. Its flagship product, Cerapro® MED Skin Barrier Cream, is a patented, CE-marked medical device approved under the European Medical Device Regulation for treating atopic dermatitis, leveraging proprietary pH-lowering technology for skin barrier repair. The company out-licenses its proprietary products to regional pharmaceutical and cosmetics partners for commercialization in target markets, receiving upfront fees, product supply revenue, and ongoing royalties.

Product overview

Hyphens Pharma International is a Singapore-based pharmaceutical group that develops and commercializes proprietary pharmaceutical and health supplement products. The company's product portfolio includes Cerapro® MED Skin Barrier Cream, a patented medical device approved under the European Medical Device Regulation for treating atopic dermatitis. The company out-licensed Cerapro® MED to Swiss company Louis Widmer SA for commercialization in six European countries (Switzerland, Liechtenstein, Austria, Belgium, Luxembourg, and Netherlands), with product launch planned for 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Cerapro® MED: Patented skin barrier cream that lowers skin pH, approved as a medical device with CE marking under the European Medical Device Regulation for treating atopic dermatitis. It is positioned as the flagship of Louis Widmer's Remederm line.

Products and services

• Cerapro® MED Skin Barrier Cream A patented skin barrier cream that lowers skin pH and is approved as a medical device with CE marking under the European Medical Device Regulation for treating atopic dermatitis. It is positioned as the flagship of Louis Widmer's Remederm line and is promoted to dermatologists and paediatricians across licensed European markets. The product addresses rising prevalence of moderate to severe eczema affecting around 20% of school-going children and 10% of adults in Singapore.

Quantifiable outcome

• Market expansion into 6 European countries through licensing partnership with Louis Widmer

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Louis Widmer SAcoreOEM/ Whitelabel/ Licensing Partner · 5 January 2026Hyphens Pharma International granted Louis Widmer SA licensing, supply, and commercialisation rights for Cerapro® MED Skin Barrier Cream covering six European countries: Switzerland, Liechtenstein, Austria, Belgium, Luxembourg, and the Netherlands. The product is a patented, CE-marked medical device for treating atopic dermatitis. Hyphens Pharma receives an upfront fee and customary royalties on sales, with product launch targeted for 2026. Louis Widmer, a Swiss cosmetics and pharmaceuticals company founded in 1960, will commercialise and promote the product to dermatologists and paediatricians, positioning Cerapro® as the flagship of its Remederm line.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• Almirall: European specialty dermatology pharma company that both develops and licenses/partner-distributes dermatology products across Southern Europe — closely aligned with Hyphens' model of regional out-licensing of proprietary dermatology brands.
• Dermapharm Holding: German specialty pharma focused on dermatology and allergy products, combining proprietary and licensed assets — closely comparable to Hyphens' specialty-pharma-and-licensing model in dermatology.
• HRA Pharma (Perrigo): European specialty consumer-healthcare and dermatology player that grows partly through licensing and regional partnerships in skin and barrier-care categories — comparable licensing-led commercial model to Hyphens.

Broad incumbents

• Galderma: Global specialty dermatology pharma major covering prescription and consumer skincare, including atopic dermatitis and sensitive-skin categories — directly comparable to Hyphens' dermatology focus but at vastly larger scale and with owned global sales infrastructure.
• Beiersdorf (Eucerin): Beiersdorf's Eucerin medical skincare range targets atopic-prone and sensitive skin with barrier repair claims, putting it in direct therapeutic and channel overlap with Cerapro® MED while operating as a global FMCG incumbent.
• LEO Pharma: Specialty dermatology pharma company with a strong atopic dermatitis franchise; comparable to Hyphens in therapeutic focus (dermatology) and reliance on dermatology KOL promotion, though LEO operates a fully owned global commercial footprint rather than regional licensing.
• Viatris (Dermatology portfolio): Global pharma company with a distributed dermatology and consumer healthcare footprint relevant to Hyphens' regional specialty-pharma positioning; representative of where off-patent dermatology assets flow over time.
• Pierre Fabre Dermatologie: French pharmaceutical and dermo-cosmetic group with a dermatology prescription and consumer franchise spanning skin barrier, sensitive skin, and atopy — directly comparable to Hyphens' medical-device-plus-skincare positioning, with own European sales infrastructure.

Regional players

• Maruho Co., Ltd. Japanese specialty dermatology pharma company with a long track record of proprietary and licensed atopic dermatitis products; comparable therapeutic focus to Cerapro® MED though primarily Asia-Japan rather than Europe.

Others

• Louis Widmer SA: Swiss dermo-cosmetics and pharmaceutical partner that has licensed Cerapro® MED for six European countries and made it flagship of its Remederm line; not a competing equivalent but the channel partner whose Remederm positioning explains Hyphens' European reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hyphens Pharma International